Amedisys Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amedisys saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 531,700 shares, an increase of 40.6% from the February 28th total of 378,100 shares. Based on an average daily volume of 196,500 shares, the short-interest ratio is presently 2.7 days.
View Amedisys' Short Interest.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for Amedisys.

Amedisys will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings results on Tuesday, February, 23rd. The health services provider reported $1.49 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.47 by $0.02. The health services provider had revenue of $550.71 million for the quarter, compared to the consensus estimate of $551.91 million. Amedisys had a net margin of 8.22% and a trailing twelve-month return on equity of 26.41%. During the same period in the previous year, the company posted $0.94 EPS.
View Amedisys' earnings history.

Amedisys issued an update on its FY21 earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of $6.25-6.47 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.33. The company issued revenue guidance of $2.275-2.315 billion, compared to the consensus revenue estimate of $2.31 billion.

12 brokerages have issued 12-month price targets for Amedisys' shares. Their forecasts range from $190.00 to $340.00. On average, they anticipate Amedisys' share price to reach $274.46 in the next twelve months.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of AMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.24%), Louisiana State Employees Retirement System (0.03%), Fulcrum Equity Management (0.02%), HMS Capital Management LLC (0.02%), State of Alaska Department of Revenue (0.02%) and Shilanski & Associates Inc. (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, State of Alaska Department of Revenue, Shilanski & Associates Inc., Pacer Advisors Inc., and First Citizens Bank & Trust Co.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

AMED stock was acquired by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Hanlon Investment Management Inc., TrimTabs Asset Management LLC, FDx Advisors Inc., HMS Capital Management LLC, Paragon Advisors LLC, Louisiana State Employees Retirement System, and Veracity Capital LLC. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Amedisys has a market capitalization of $0.00 and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis.

Amedisys employs 21,000 workers across the globe.

Amedisys was founded in 1982.

The official website for Amedisys is www.amedisys.com.

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]